AtriCure (ATRC) Expected to Announce Quarterly Earnings on Wednesday

AtriCure (NASDAQ:ATRC) is expected to be issuing its Q3 2025 results after the market closes on Wednesday, October 29th. Analysts expect the company to announce earnings of ($0.11) per share and revenue of $131.2530 million for the quarter. AtriCure has set its FY 2025 guidance at -0.390–0.340 EPS.Parties are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Wednesday, October 29, 2025 at 4:30 PM ET.

AtriCure (NASDAQ:ATRC) last posted its quarterly earnings data on Tuesday, July 29th. The medical device company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.13. AtriCure had a negative return on equity of 4.20% and a negative net margin of 7.27%.The company had revenue of $136.14 million for the quarter, compared to the consensus estimate of $130.17 million. During the same period in the previous year, the business earned ($0.17) EPS. AtriCure’s revenue for the quarter was up 17.1% compared to the same quarter last year. On average, analysts expect AtriCure to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

AtriCure Price Performance

ATRC stock opened at $37.54 on Monday. The company has a quick ratio of 2.83, a current ratio of 3.94 and a debt-to-equity ratio of 0.16. AtriCure has a 52-week low of $27.64 and a 52-week high of $43.11. The stock’s 50 day moving average is $36.10 and its two-hundred day moving average is $33.85. The company has a market capitalization of $1.87 billion, a PE ratio of -48.75 and a beta of 1.59.

Insider Buying and Selling

In related news, insider Justin J. Noznesky sold 3,000 shares of the company’s stock in a transaction on Friday, September 12th. The stock was sold at an average price of $36.30, for a total transaction of $108,900.00. Following the completion of the transaction, the insider directly owned 83,964 shares in the company, valued at $3,047,893.20. This represents a 3.45% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Vinayak Doraiswamy sold 2,500 shares of the business’s stock in a transaction on Tuesday, August 5th. The stock was sold at an average price of $36.58, for a total value of $91,450.00. Following the transaction, the insider owned 71,872 shares of the company’s stock, valued at $2,629,077.76. This trade represents a 3.36% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 17,952 shares of company stock valued at $655,633 in the last 90 days. Corporate insiders own 3.50% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in ATRC. Geneos Wealth Management Inc. acquired a new position in AtriCure during the 2nd quarter worth $37,000. Strs Ohio acquired a new position in AtriCure during the 1st quarter worth $158,000. Tower Research Capital LLC TRC boosted its position in AtriCure by 502.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,492 shares of the medical device company’s stock worth $180,000 after acquiring an additional 4,581 shares during the period. State of Tennessee Department of Treasury acquired a new position in AtriCure during the 2nd quarter worth $184,000. Finally, Prudential Financial Inc. acquired a new position in AtriCure during the 2nd quarter worth $215,000. Institutional investors and hedge funds own 99.11% of the company’s stock.

Wall Street Analysts Forecast Growth

ATRC has been the topic of several analyst reports. BTIG Research set a $54.00 price objective on AtriCure in a report on Wednesday, July 30th. Wall Street Zen upgraded AtriCure from a “hold” rating to a “buy” rating in a report on Saturday, August 2nd. Needham & Company LLC boosted their price target on AtriCure from $44.00 to $45.00 and gave the company a “buy” rating in a report on Wednesday, July 30th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of AtriCure in a report on Friday. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $50.89.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.